P
Philip J. O'Connell
Researcher at University of Sydney
Publications - 244
Citations - 11348
Philip J. O'Connell is an academic researcher from University of Sydney. The author has contributed to research in topics: Transplantation & Islet. The author has an hindex of 49, co-authored 227 publications receiving 10207 citations. Previous affiliations of Philip J. O'Connell include Beth Israel Deaconess Medical Center & Westmead Hospital.
Papers
More filters
Journal ArticleDOI
The natural history of chronic allograft nephropathy.
Brian J. Nankivell,Richard Borrows,Caroline L.-S. Fung,Philip J. O'Connell,Richard D. M. Allen,Jeremy R. Chapman +5 more
TL;DR: Chronic allograft nephropathy represents cumulative and incremental damage to nephrons from time-dependent immunologic and nonimmunologic causes, and was irreversible, resulting in declining renal function and graft failure.
Journal ArticleDOI
Improvement in outcomes of clinical islet transplantation: 1999-2010.
Franca B. Barton,Michael R. Rickels,Rodolfo Alejandro,Bernhard J. Hering,Stephen Wease,Bashoo Naziruddin,Jose Oberholzer,Jon S. Odorico,Marc R. Garfinkel,Marlon F. Levy,François Pattou,Thierry Berney,Antonio Secchi,Shari Messinger,Peter A. Senior,Paola Maffi,Andrew M. Posselt,Peter G. Stock,Dixon B. Kaufman,Xunrong Luo,Fouad Kandeel,Enrico Cagliero,Nicole A. Turgeon,Piotr Witkowski,Ali Naji,Philip J. O'Connell,Carla J. Greenbaum,Yogish C. Kudva,Kenneth L. Brayman,Meredith J. Aull,Christian P. Larsen,Thomas W.H. Kay,Luis A. Fernandez,Marie-Christine Vantyghem,Melena D. Bellin,A. M. James Shapiro +35 more
TL;DR: The CITR shows improvement in primary efficacy and safety outcomes of islet transplantation in recipients who received transplants in 2007–2010 compared with those in 1999–2006, with fewer islet infusions and adverse events per recipient.
Journal ArticleDOI
Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol Histology
Brian J. Nankivell,Richard Borrows,Caroline L.-S. Fung,Philip J. O'Connell,Jeremy R. Chapman,Richard D. M. Allen +5 more
TL;DR: CsA is unsuitable as a universal, long-term immunosuppressive agent for kidney transplantation and strategies to ameliorate or avoid nephrotoxicity are thus urgently needed.
Journal ArticleDOI
Loss of ARNT/HIF1β Mediates Altered Gene Expression and Pancreatic-Islet Dysfunction in Human Type 2 Diabetes
Jenny E. Gunton,Rohit N. Kulkarni,Sun Hee Yim,Terumasa Okada,Wayne J. Hawthorne,Yu-Hua Tseng,Russell S. Roberson,Camillo Ricordi,Philip J. O'Connell,Frank J. Gonzalez,C. Ronald Kahn +10 more
TL;DR: Using oligonucleotide microarrays and real-time PCR of pancreatic islets isolated from humans with type 2 diabetes versus normal glucose-tolerant controls and beta cell-specific ARNT knockout mice, data suggest an important role for decreased ARNT and altered gene expression in the impaired islet function of human type 1 diabetes.
Journal ArticleDOI
Chronic Renal Allograft Dysfunction
TL;DR: There have been a number of approaches to treatment aimed at reducing the impact of CAN, mostly centered around avoidance of calcineurin inhibitors through their elimination in all, or just selected, patients.